Literature DB >> 16452995

Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension.

L C Rump, E Ambrosioni, M Burnier, W Hörl, A J Rabelink.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16452995     DOI： 10.1038/sj.jhh.1001984

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN： 0950-9240            Impact factor:   3.012


× No keyword cloud information.
  6 in total

Review 1.  Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

Review 2.  Olmesartan medoxomil: a review of its use in the management of hypertension.

Authors:  Lesley J Scott; Paul L McCormack
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study.

Authors:  Roberto Fogari; Annalisa Zoppi; Amedeo Mugellini; Paola Preti; Maurizio Destro; Andrea Rinaldi; Giuseppe Derosa
Journal:  Curr Ther Res Clin Exp       Date:  2008-02

Review 4.  Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension.

Authors:  Mark Greathouse
Journal:  Vasc Health Risk Manag       Date:  2006

5.  Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study.

Authors:  Vivencio Barrios; Carlos Escobar; Alberto Calderon; Michael Böhm
Journal:  Vasc Health Risk Manag       Date:  2009-09-07

Review 6.  Emerging insights in the first-step use of antihypertensive combination therapy.

Authors:  Keith Norris; Joel M Neutel
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-12       Impact factor: 3.738
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.